Good Survival, Outcomes With TARE for HCC medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
DOORwaY-90 study for SIR-Spheres® therapy as first-line treatment for hepatocellular carcinoma enrolls first patient
May 10, 2021 GMT
Sirtex DOORwaY-90 Study Logo
First prospective multicenter U.S.-based trial for indication expansion of SIR-Spheres® Y-90 resin microspheres taking place in 15 sites across the U.S.
WOBURN, Mass., May 10, 2021 /PRNewswire/ Sirtex Medical (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced that the first patient has been enrolled in DOORwaY-90, a study evaluating the safety and efficacy of selective internal radiation therapy (SIRT) using SIR-Spheres® Y-90 resin microspheres in patients with unresectable hepatocellular carcinoma (HCC).
Antibiotics May Prolong PFS in HCC Patients on Immunotherapy medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.
COVID-19 First Wave Declined Liver Cancer Care by Angela Mohan on February 9, 2021 at 3:15 PM
Liver cancer care has been drastically reduced in the view of first wave of COVID-19. The delays of screening programmes, diagnostic imaging and biopsies, cuts in the numbers of physicians available to treat liver cancer patients, cancellations of surgery, and a drop in the number of patients entered on clinical trials, were just some of the issues reported in the poll.
The global Liver Cancer Outcomes in COVID-19 (CERO-19) Survey led by the Barcelona Clinic Liver Cancer (BCLC) group from Hospital Clinic of Barcelona, CIBEREH, and the Ospedale Maggiore Policlinico of Milan included 76 high-volume cancer treatment centres which participated during the first wave of the COVID-19 pandemic between March and June 2020, finding that 87% of centres modified clinical practice for liver cancer patients. These centres spanned Europe, North America, South America, Africa, and